Anavex Life Sciences remains a pre-revenue biotechnology firm entirely dependent on external financing to fund its late-stage CNS pipeline, as evidenced by cumulative retained earnings losses of $388.1 million. While the company maintains a debt-free balance s...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 28, 2026 | -$0.03+62.5% vs -$0.08 | — vs — |
Q3 2026 Aug 25, 2026 | $0.08+200.0% vs -$0.08 | — vs — |
Q3 2026 Aug 18, 2026 | -$0.06+25.0% vs -$0.08 | — vs — |
Q3 2026 Aug 17, 2026 | -$0.06+25.0% vs -$0.08 | — vs — |
-- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders – -- Believes Anavex Needs New Leadership with Deep Industry Experience and Credible Strategic Plan to Turn the Company Around and Unlock Value for Shareholders –
-- Proxy advisor recommends voting “ FOR” two of PVG's director nominees and “AGAINST” two incumbent director nominees including the board's current chair on the GOLD Universal Proxy Card –
Anavex Life Sciences Corp. (AVXL) Discusses Board Misalignment, Leadership Concerns, and Strategic Changes for Company Turnaround Transcript
-- Yet ISS gives Anavex Board a free pass on years of failed governance and shareholder value destruction by supporting the current board's nominees –
Benchmark AVXL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Anavex Life Sciences Corp. (AVXL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.35 | $217.78M | -4.35 | — | — | -43.11% | — | |
| $0.94 | $45.26M | -1.80 | — | — | -95.77% | — | |
| $282.12 | $7.87B | -20.93 | -100% | — | -34.15% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $1.18 | $37.02M | -1.08 | — | 32.23% | 83.42% | — | |
| $227.53 | $33.62B | 25.77 | 1.39% | 8.39% | 4.52% | — |
Anavex Life Sciences Corp. (AVXL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Anavex Life Sciences Corp. (AVXL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 9, 2026·SEC
Sep 2, 2026·SEC
Aug 25, 2026·SEC
Get notified when AVXL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Anavex Life Sciences Corp. (AVXL) stock FAQ — growth, dividends, profitability & financials explained
Anavex Life Sciences Corp. (AVXL) reported a net loss of $31.9M for fiscal year 2025.
Anavex Life Sciences Corp. (AVXL) has a return on equity (ROE) of -43.1%. Negative ROE indicates the company is unprofitable.
Anavex Life Sciences Corp. (AVXL) had negative free cash flow of $41.8M in fiscal year 2025, likely due to heavy capital investments.
